Hey y'all, I'm feeling pretty lazy tonight and melsdollars

New Post Public Reply Private Reply Replies (3) Message Board
Respert24
943
Hey y'all, I'm feeling pretty lazy tonight and melsdollars had a killer post already.

(Great work mels)

So instead of coming up with something all on my own, which seems taxing, I decided to just turn Mels post into a Respert post. Way less effort since all the hard work is done. So forget everything you just read and please enjoy this completely original and unique take on our current situation.

Re: Collaboration –

Of all the theories about what's going on behind the scenes at Cytodyn, a potential partnership with Qilu Pharma seems to make the most sense. It's a jigsaw of a puzzle, but the pieces do seem to fit together. And as I’ve been teaching the local middle school boys I mentor, if it doesn’t want to fit you just keep pushing until it goes in.

Qilu is apparently a Chinese pharma company doing business in over 70 countries, but I’m not fully convinced it isn’t just three Naders standing on each other’s shoulders and wearing a trench coat. I mean, they’re basically saying they want to partner with companies that have Leronlimab. If you read between the trench coat, that is.

You couldn’t draw it up better if you were Gary Larson. And if you don’t get the reference I’d suggest you look it up, ya dilberts.

(You just got comic strip burned)

Qilu is the manufacturer or Carboplatin, the drug Leronlimab is in trials with at MD Anderson Cancer Center.

Boom.

Dr. Ray returned to Cytodyn as VP of Licensing and Business Development in November. Dr. Ray formerly worked for Qilu Phama as their Senior VP of Licensing. He negotiated Qilu's licensing deal with Arbutus Biopharma. I normally don’t allow butt stuff, but Arbutus is spelled with only one T so I’m allowing it. (But watch yourself counselor)

Boom.

Sidely Austin helped establish the company Arbutus Biopharma which eventually partnered with Qilu.

Double Boom.

Sidley Austin is counsel for Xynomic Pharma, handling their merger with Bison Capital. Xynomic's Vice President is Yong Cui, formerly VP of R&D for Qilu.

I like the cut of this Bison Capital’s jib. Strong name. Time for a quick tangent.

There’s a restaurant in Metro Detroit that specializes in wild game, eschewing the usual sirloins and strips for meats like Bison or Emu. Two memories crept up as I read the word Bison. The first is that Emu tastes exactly like filet mignon. The second memory is that it was at that restaurant that I broke out a dumb joke for the first time that has become one of my favorites to employ amongst friends and coworkers: My female teammate, who happened to be only a few years older than me, ordered her meal and I realized I’d be ordering the same thing. So when the waiter got to me and asked what I wanted, I responded with “I’ll have the same thing my mom is having” and it went over about as well as you can imagine. But I loved it, which is all that mattered.

For my own personal enjoyment it's right up there with “could you seat us somewhere romantic?” when eating out with buddies. Ok, back to the story.

Oh, and I almost forgot…

Boom.

Sidley was counsel of record in a patent dispute, Janssen v. Qilu. By the way, that’s not a spelling error. They really use two esses when spelling their own name like a bunch of morons. I hope they lost that lawsuit.

Gavel Boom.

Sidley has offices all over the world, including Beijing and Hong Kong.

Geography Boom, bitches.

- - - -

In my opinion, a potential partnership has been in the works for some time and if you can’t see it, to quote the great investor Robert Diggs of Wu-Tang Financial, you couldn’t cut your way out of a wet paper bag…with scissors in your hand.

FACT: Dr. Ray worked for Cytodyn before. He would not return unless there was a viable product for development.

FACT: Dr. Scott Kelly specifically mentioned China when discussing potential partnerships in the December conference call.

FACT-ADJACENT: The Leronlimab trial with Qilu's Carboplatin could be a 'proof of concept' situation. You know, the old “let me get a little bump to make sure you’ve got the good stuff.” Then just a few weeks later they’re offering ZJ’s under the overpass to try to afford just a little more of that sweet, sweet Leronlimab. Now they’re ready to really pony up.

What’s a ZJ?

If you have to ask, you can’t afford it.

Now, consider that Sidley Austin could have been in discussions with Cytodyn regarding collaborations all the way back when the 13d(bags) nonsense started. So retaining Sidley to defend the 13d(bag) takeover was a lucky happenstance that Cytodyn took advantage of.

Like when you’re out in public wearing your “I’m Respert24” t-shirt and the ladies just throw themselves at you. You don’t say, “hey, I’m not Respert, I’m just a fan”. No, you jokingly say “no butt stuff” while laughing, and then you invite them back to the hotel where you’ll double back on your word.

With consent of course, ya dilberts.

Anyway, it seems clear now that Pourhassan was voted back in to maintain the status quo, until the next phase. Which, since nobody has named it yet, we’ll call Phase 2: Electric Boogaloo.

We are now in a quiet period, so stop posting about how you’ve emailed someone from Cytodyn and they’ve yet to respond. Yeah, of course they haven’t responded. They can’t. Not until the ink is dry on the deal. Until then they have to shut up. In fact, maybe moving Nader on was originally going to happen after the ink was dry, because he’s said numerous times that he’d move on when the time was right, but then they realized that loose lips sink ships and Nader has been rocking flabby old-lady-tits-type-lips (medical term) for years now and was too risky to keep around.

Listen, these are just facts. Melsdollars knows what I’m talking about.

All will be clear very soon. In the meantime, strong and long CYDY!

Respertfully yours,

Evening Respert24

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

IQSTEL's Nine-Month Revenue Hits $313M, Growth Impresses

Updated Category News Views 151

Pushing Through With Persistence Well, well, well, here we are, talking about IQSTEL Inc. (NASDAQ: IQST) slinging some serious numbers—not the kind you can ignore at your breakfast table. The company pulled in a whopping $313 million in revenue over the first nine months of 2026. That’s a bump up by 34.5% from last year’s $232.7 million. What’s behind the magic...

Continue Reading
LONGWELL's New Axial Fan Selection Guide Unveiled

Updated Category News Views 88

LONGWELL's New Fan Brochure Shakes Up Data Center Cooling Alright, let's cut to the chase. LONGWELL, the folks out in Ningbo who live and breathe HVACR and industrial fans, have dropped a new tool that’s going to have OEM engineers raising a glass. This twelve-page axial fan selection guide is a stroke of genius—or at least that's what those of us who've braved the...

Continue Reading
WHP Global's Japan Move: A Major Toy Market Play

Updated Category News Views 113

New Horizons for Toys"R"Us in Japan Well, folks, look who's back in the toy game with a vengeance! WHP Global is shaking hands with Pan Pacific International Holdings (PPIH) to breathe new life into Toys"R"Us across Japan. Now PPIH isn’t just any player. We're talking about Japan's fourth-largest retailer, helming giants like Don Quijote and aiming to crown itself as...

Continue Reading
Apotex Enters U.S. Market with Axitinib Tablets Launch

Updated Category News Views 89

Apotex's Bold Move: Axitinib Tablets Hit the U.S. Market Apotex is shaking things up in the pharma world by launching the first generic version of Axitinib Tablets in the U.S., aimed at treating advanced renal cell carcinoma (RCC) when previous treatments have fallen flat. This isn't just another dance with the red tape—it's a major step for Apotex, flexing their muscle...

Continue Reading
HLTH USA 2026 Spotlights AI and Health Innovation

Updated Category News Views 82

The Pulse of Innovation at HLTH USA 2026 Diving headfirst into the heart of healthcare innovation, HLTH USA 2026 kicked off with gusto in Las Vegas. Discussions are swirling around AI advancements and the next generation of payer-provider collaboration. Who knew healthcare could be this thrilling? The event is already shaping up to be a powerhouse of change, buzzing with...

Continue Reading
WirelessCar Rebrands to Reinforce Connected Mobility Vision

Updated Category News Views 122

Evolving Identity for Changing Times Let’s dive right into it—WirelessCar, a name that’s struck chords in the automotive trenches for ages, is taking a bold step by unveiling a new brand identity. Now, don’t roll your eyes just yet. This isn’t another company tapping the rebranding siren for the heck of it. We’re talking about a company that’s been in the...

Continue Reading
Asia-Pacific Miracle: New Economic Chapter Unfolds

Updated Category News Views 147

A Fresh Breeze in Asia-Pacific's Sails You ever look around and realize everything's about to change—again? That's Asia-Pacific right now. We're staring down the barrel of a new chapter in what folks are calling the "Asia-Pacific miracle." The text from China Daily paints a picture of a region gearing up to crank the cooperation dial even higher. And where's this...

Continue Reading
Investors, Portillo's Fraud Claims Demand Your Attention

Updated Category News Views 30

Portillo's Investors Caught in a Tough Spot Ah, Portillo's. You thought those hot dogs were the only spicy thing you're biting into? Try these allegations on for size. Investors are biting back with a securities fraud lawsuit, and the details are saltier than a bucket of fries. The folks who held PTLO shares between September 19, 2023, and May 4, 2026, are in the...

Continue Reading
Exploring Why Dead Outlets Stay Dead: Expert Insights

Updated Category News Views 92

The Mystery of Non-Responsive Outlets Ever found an electrical outlet refusing to cooperate when you need it most? Well, I know the frustration all too well. You'd think if the breaker ain't blown, the outlet should work like a charm. But dive into the guts of the story, and you find a series of surprises waiting to trip us up. Common Culprits: Tripped GFCIs and Loose...

Continue Reading
Engrain's Geospatial Innovation Pushes Property Mapping Forward

Updated Category News Views 125

Pushing the Boundaries of Property Mapping How far can you expand the boundaries of property mapping tech? Well, Engrain seems hell-bent on finding out by cranking their innovations up a notch. The Denver-based stalwart in interactive mapping is rolling out some mind-boggling enhancements that could redefine how the multifamily housing sector operates. This isn't just...

Continue Reading

Top 5 Most Recently Viewed Articles

Earnings Insights: Key Players Ford, McDonald's, and Ferrari

Updated Category News Views 155

Anticipating Earnings Reports from Major Companies As we approach the upcoming earnings reports for several key players in the auto and consumer sectors, attention shifts towards Ford, McDonald's, and Ferrari. Understanding performance in this challenging market has never been more crucial. Each company faces unique circumstances that may influence their financial...

Continue Reading
Parsons Corporation Boosts Share Buyback Authorization to $250M

Updated Category News Views 277

Parsons Corporation Boosts Share Buyback Authorization to $250M Parsons Corporation (NYSE: PSN), a notable player in the national security and global infrastructure sectors, has made a significant decision by increasing its stock repurchase authorization to $250 million. This strategic move, announced recently, is set against the backdrop of robust operating results and...

Continue Reading
India's Foreign Exchange Reserves Show Declining Trends

Updated Category News Views 439

Understanding India's Forex Reserves Decline India's foreign exchange reserves have recently captured attention as they have been on a downward trajectory, marking a notable low. As reported, the reserves fell to $625.87 billion, a level not seen in ten months. This decline represents a significant drop of $8.72 billion in just one week, emphasizing the considerable...

Continue Reading
Efekta Education Ups the Ante with Matt Fisher as CTO

Updated Category News Views 16

AI Veteran Matt Fisher Joins Efekta as CTO You know that moment when an industry veteran steps into a key role and you just feel the tide shifting? That's what we've got on our hands with Efekta Education snapping up Matt Fisher. This isn't just any hire; Fisher's a heavyweight tech player, a regular whiz kid from tech giants like Microsoft and Amazon. He’s been around...

Continue Reading
James River Group Enhances Leadership with New Strategic Appointments

Updated Category News Views 186

James River Group Strengthens E&S Leadership Team PEMBROKE, Bermuda — James River Group Holdings, Ltd. (NASDAQ: JRVR) has taken a significant step forward in its growth strategy with the recent appointments of Georgia Collier and Matt Sinosky to its Excess and Surplus (E&S) leadership team. They will report to Todd Sutherland, the President of E&S, as the company aims...

Continue Reading